GlobeNewsWire
25 Aug 2026, 22:35 UTC · 8w ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
Impact · against what's priced in
Emergent BioSolutions faces significant fundamental deterioration and legal risk following a revenue guidance cut, a $191.3 million impairment of its NARCAN assets, and a securities fraud investigation. Azenta and Abeona Therapeutics also face increased legal uncertainty due to separate investigations by Pomerantz LLP.
- EBS−0.80
No priced-in read yet





